title: Tumor suppressor gene alterations in malignant gliomas: histopathological associations and prognostic evaluation.
abstract: We have examined a series of 135 gliomas for alterations of the p53, CDKN2A (p16) and PTEN tumor suppressor genes (TSGs) in order to evaluate the incidence of their inactivation as a function of tumor malignancy and cellular differentiation, and to examine potential associations with patient outcome. The composition of this series, classified using WHO criteria, is as follows: 27 grade 2 tumors (11 astrocytomas, 12 oligoastrocytomas, 4 oligodendrogliomas), 42 grade 3 tumors (22 astrocytomas, 16 oligoastrocytomas, 4 oligodendrogliomas), and 66 grade 4 tumors (63 astrocytomas and 3 oligoastrocytomas). Similar frequencies of p53 mutation were observed among grade 2 (37.0%), and grade 3 tumors (38.1%), as well as between astrocytomas and mixed tumors. CDKN2A and PTEN mutations were clearly associated with increasing tumor malignancy (occurring in 0% of grade 2 tumors, 14.3% and 4.8% respectively of grade 3 tumors, and 27.3% and 30.3% respectively of grade 4 tumors) and were observed at substantially higher rates among astrocytomas. For the tumor suppressor genes examined, there was no relationship between the occurrence of any two TSG inactivation events. With regard to outcome, the p53 genetic status showed no significant relationship with patient survival. The CDKN2 and PTEN alterations were negative prognostic indicators of survival when evaluated in all 135 gliomas, but failed to predict outcome when evaluated in either of the high grade (3 or 4) tumor groups.
authors.affiliation: Department of Laboratory Medicine and Pathology, Mayo Clinic and Foundation, Rochester, MN 55905, USA.
authors.forename: C D
authors.initials: CD
authors.lastname: James
authors.forename: E
authors.initials: E
authors.lastname: Galanis
authors.forename: L
authors.initials: L
authors.lastname: Frederick
authors.forename: D W
authors.initials: DW
authors.lastname: Kimmel
authors.forename: J M
authors.initials: JM
authors.lastname: Cunningham
authors.forename: P J
authors.initials: PJ
authors.lastname: Atherton-Skaff
authors.forename: J R
authors.initials: JR
authors.lastname: O'Fallon
authors.forename: R B
authors.initials: RB
authors.lastname: Jenkins
authors.forename: J C
authors.initials: JC
authors.lastname: Buckner
authors.forename: S B
authors.initials: SB
authors.lastname: Hunter
authors.forename: J J
authors.initials: JJ
authors.lastname: Olson
authors.forename: B W
authors.initials: BW
authors.lastname: Scheithauer
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002675:Child, Preschool; D005069:Evaluation Studies as Topic; D005260:Female; D016147:Genes, Tumor Suppressor; D019942:Genes, p16; D016158:Genes, p53; D005910:Glioma / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D051059:PTEN Phosphohydrolase; D010744:Phosphoric Monoester Hydrolases / Q000235:genetics; D016133:Polymerase Chain Reaction; D011379:Prognosis; D015996:Survival Rate; D025521:Tumor Suppressor Proteins
chemical_list: D025521:Tumor Suppressor Proteins; D010744:Phosphoric Monoester Hydrolases; D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human